Stocktoria
Aurobindo Pharma Limited AUROPHARMA.NS
IN · National Stock Exchange of India · XNSE · stock · Healthcare · website
Aurobindo Pharma Limited financials (annual)
Bars are annual figures from 2023 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | ₹333.8B | ₹313.8B | ₹287.0B | ₹246.2B |
| Gross profit | ₹199.0B | ₹183.5B | ₹154.7B | ₹127.2B |
| R&D expense | — | ₹951.0M | ₹756.3M | ₹395.1M |
| SG&A expense | — | ₹30.6B | ₹25.0B | ₹23.5B |
| Operating income | ₹50.8B | ₹49.6B | ₹44.4B | ₹25.4B |
| Interest expense | ₹3.8B | ₹4.6B | ₹2.7B | ₹1.3B |
| Income tax | ₹16.1B | ₹15.8B | ₹12.1B | ₹6.8B |
| Net income | ₹35.0B | ₹34.9B | ₹31.7B | ₹19.3B |
| EPS (diluted) | — | ₹59.81 | ₹54.16 | ₹32.90 |
| Operating cash flow | ₹55.3B | ₹39.2B | ₹24.3B | ₹23.9B |
| Free cash flow | ₹24.2B | ₹14.1B | -₹11.3B | -₹3.3B |
| Cash & equivalents | ₹71.9B | ₹55.7B | ₹33.9B | ₹44.0B |
| Inventory | ₹120.5B | ₹105.4B | ₹98.1B | ₹85.1B |
| Goodwill | ₹8.0B | ₹6.2B | ₹6.0B | ₹6.0B |
| Total assets | ₹585.0B | ₹497.8B | ₹450.7B | ₹398.9B |
| Total debt | ₹80.7B | ₹82.6B | ₹66.5B | ₹52.9B |
| Total liabilities | ₹206.2B | ₹171.4B | ₹152.2B | ₹130.4B |
| Shareholders' equity | ₹378.9B | ₹326.5B | ₹298.4B | ₹268.4B |
| Share buybacks | ₹0 | ₹9.3B | ₹0 | — |
Growth · year-over-year · Revenue CAGR 10.7%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue growth | +6.4% | +9.3% | +16.6% | — |
| Net income growth | +0.5% | +9.9% | +64.6% | — |
| EPS growth | — | +10.4% | +64.6% | — |
| Free cash flow growth | +72.4% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.